Why Ashland’s latest earnings and governance moves matter for shareholders

Ashland (ASH) has just reported third quarter and year to date results that shifted from heavy losses last year to profits, reaffirmed full year sales guidance, and agreed a cooperation deal with investor Ancora.

The company reported third quarter sales of US$497 million, with net income of US$16 million after a net loss of US$742 million a year earlier. Diluted earnings per share from continuing operations were US$0.89, compared with a diluted loss per share from continuing operations of US$15.70 in the prior year period.

On a consolidated basis, diluted earnings per share were US$0.35 for the quarter, versus a diluted loss per share of US$16.21 a year ago. For many investors, that shift from loss to profit is likely to be a key reference point when tracking how Ashland is performing against its own history.

For the first nine months ended June 30, 2026, Ashland reported sales of US$1,365 million compared with US$1,347 million a year ago. Net income for the period was US$20 million after a net loss of US$877 million in the prior year, and diluted earnings per share from continuing operations were US$0.91 compared with a diluted loss per share from continuing operations of US$18.39.

Total diluted earnings per share for the nine months were US$0.43, versus a diluted loss per share of US$18.85 in the prior year period. These figures give you a clearer base to compare any future results against, rather than focusing only on share price moves.

Ashland’s recent earnings recovery and cooperation agreement with Ancora have arrived alongside a 90 day share price return of 31.72% and a 1 year total shareholder return of 41.44%. However, 3 and 5 year total shareholder returns remain slightly negative, which suggests momentum has picked up more recently rather than over the longer term.

If Ashland’s shift back to profit has you reassessing your watchlist, this can be a good moment to widen the search and review 20 top founder-led companies

Ashland’s earnings swing and 31.72% 90 day share price move put you at a fork in the road. Has the market already priced in most of the recovery, or does the current valuation still leave meaningful upside on the table?

Most Popular Narrative: 1.6% Undervalued

Ashland’s most followed valuation narrative pegs fair value at about $73.64 per share, just above the last close of $72.46, which points to a very small discount and a finely balanced outlook.

The global shift toward sustainable and bio-based materials driven by regulatory requirements and consumer preference continues to gain momentum, benefiting Ashland's specialty chemicals portfolio that is now more focused on high-value, sustainable, and compliant solutions. This is expected to support top-line revenue growth and margin resilience over the long term.

Want to see what sits behind that fair value call for Ashland? The narrative leans on steady revenue gains, rising margins, and a future earnings profile that needs a different valuation multiple to add up. Curious which assumptions carry the most weight in that equation? The full breakdown sets out the numbers and how they connect.

Result: Fair Value of $73.64 (UNDERVALUED)

However, Ashland still faces pressure points. Prolonged softness in Specialty Additives demand and the earlier US$706 million goodwill impairment could both challenge the current recovery narrative.

Next Steps

With both risks and rewards on the table for Ashland, this is a good time to review the data yourself and decide where you stand. To size up both sides in one place, take a closer look at the 3 key rewards and 2 important warning signs.

Looking for more investment ideas beyond Ashland?

If Ashland has sharpened your focus, do not stop here. Fresh ideas can help keep your portfolio balanced and prepared for a range of market conditions.

• Explore potential income opportunities and review companies that have paid investors consistently by checking out the 9 dividend fortresses.
• Search for quality at a sensible price and review companies that appear attractively priced using the 51 high quality undervalued stocks.
• Limit unexpected changes in your portfolio and focus on companies with steadier profiles through the 78 resilient stocks with low risk scores.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.